Women at Risk of Breast Cancer and OLFM4

NAActive, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 8, 2016

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Hereditary Breast and Ovarian Cancer Syndrome

Interventions

BIOLOGICAL

OLFM4

patient have an additional blood test every 6 months for dosing OLFM4

Trial Locations (4)

CHU Morvan, Brest

Instit de Cancérologie de l'Ouest, Nantes

Institut de Cancerologie de l'Ouest, Angers

CHBA Hopital Chubert, Vannes

All Listed Sponsors

lead

Institut Cancerologie de l'Ouest

OTHER

NCT02653105 - Women at Risk of Breast Cancer and OLFM4 | Biotech Hunter | Biotech Hunter